使用或不使用贝伐单抗治疗转移性结直肠癌：中性粒细胞/淋巴细胞比值能否预测贝伐单抗的疗效？
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
作者信息
Dirican Ahmet, Varol Umut, Kucukzeybek Yuksel, Alacacioglu Ahmet, Erten Cigdem, Somali Isil, Can Alper, Demir Lutfiye, Bayoglu Ibrahim Vedat, Akyol Murat, Yildiz Yasar, Koyuncu Betul, Coban Eyup, Tarhan Mustafa Oktay
机构信息
Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey E-mail :
出版信息
Asian Pac J Cancer Prev. 2014;15(12):4781-6. doi: 10.7314/apjcp.2014.15.12.4781.
BACKGROUND
The purpose of this study was to analyze the predictive value of neutrophil/lymphocyte ratio (NLR) to better clarify which patient groups will benefit the most from particular treatments like bevacizumab.
MATERIALS AND METHODS
A total of 245 treatment-naive metastatic colorectal cancern (mCRC) patients were retrospectively enrolled and divided into 2 groups: 145 group A patients were treated with chemotherapy in combination with bevacizumab, and 100 group B patients were treated as above without bevacizumab.
RESULTS
Group A patients had better median overall survival (OS) and progression-free survival (PFS) (24.0 and 9.0 months) than group B patients (20 and 6.0 months) (p=0.033; p=0.015). In patients with low NLR, OS and PFS were significantly longer in group A patients (27 vs 18 months, p=0.001; 11 vs 7 months, p=0.017).
CONCLUSIONS
We conclude that NLR, a basal cancer related inflammation marker, is associated with the resistance to bevacizumab- based treatments in mCRC patients.
背景
本研究旨在分析中性粒细胞/淋巴细胞比值（NLR）的预测价值，以更好地阐明哪些患者群体将从贝伐单抗等特定治疗中获益最大。
材料与方法
共回顾性纳入245例未经治疗的转移性结直肠癌（mCRC）患者，并分为两组：145例A组患者接受化疗联合贝伐单抗治疗，100例B组患者接受上述不含贝伐单抗的治疗。
结果
A组患者的中位总生存期（OS）和无进展生存期（PFS）（分别为24.0个月和9.0个月）优于B组患者（分别为20个月和6.0个月）（p = 0.033；p = 0.015）。在NLR较低的患者中，A组患者的OS和PFS显著更长（27个月对18个月，p = 0.001；11个月对7个月，p = 0.017）。
结论
我们得出结论，NLR作为一种基础癌症相关炎症标志物，与mCRC患者对基于贝伐单抗治疗的耐药性相关。
Zotero 插件